Company
Headquarters: London, United Kingdom
Employees: 24
CEO: Mr. James Gareth Short
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.
| Last Financial Reports Date | June 30, 2023 |
| Revenue TTM | £21,000 |
| EBITDA | £-6,958,000 |
| Gross Profit TTM | £-66,000 |
| Profit Margin | -275.00% |
| Operating Margin | -45100.00% |
| Quarterly Revenue Growth | -27.30% |
Celadon Pharmaceuticals Plc has the following listings and related stock indices.
Stock: LSE: CEL wb_incandescent